According to the treatment criteria of the APASL guideline [4], this 460 patients with ALT <2 × ULN should monitor ALT level every 3 months, biopsy was considered if ALT was persistently elevated, noninvasive tests suggested evidence of significant fibrosis, age > 35 years or family h/o HCC or cirrhosis. This evidence concerns the gene GPT and Cirrhosis.